Literature DB >> 35816991

Association of PD-L1 expression, tumor mutational burden and immunotherapy with venous thrombosis in patients with solid organ malignancies.

Rajat Thawani1, Thomas Kartika2, Benjamin Elstrott3, Elizabeth Batiuk3, Derrick Tao4, Sonia Gowda5, Lilian Chen3, Corinne Lavasseur5, Nattapron Tun5, Nicholas F Taflin5, Joseph Shatzel6.   

Abstract

Entities:  

Keywords:  Cancer-associated thrombosis; Immunotherapy; Venous thrombosis

Mesh：

Substances：

Year:  2022        PMID： 35816991      PMCID： PMC9464501          DOI： 10.1016/j.thromres.2022.06.012

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   10.407


× No keyword cloud information.
  9 in total

1.  Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.

Authors:  Florian Moik; Wei-Shin Evelyn Chan; Sarah Wiedemann; Christoph Hoeller; Felix Tuchmann; Marie-Bernadette Aretin; Thorsten Fuereder; Sabine Zöchbauer-Müller; Matthias Preusser; Ingrid Pabinger; Cihan Ay
Journal:  Blood       Date:  2021-03-25       Impact factor: 22.113

2.  Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.

Authors:  Oded Icht; Naama Darzi; Shai Shimony; Oded Jacobi; Daniel Reinhorn; Yosef Landman; Raz Mutai; Itamar Averbuch; Tzippy Shochat; Galia Spectre; Pia Raanani; Ofer Rotem; Elizabeth Dudnik; Nir Peled; Alona Zer; Avi Leader
Journal:  J Thromb Haemost       Date:  2021-03-16       Impact factor: 5.824

3.  PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC).

Authors:  Pedro De Marchi; Leticia Ferro Leal; Vinicius Duval da Silva; Eduardo Caetano Albino da Silva; Vladmir Claudio Cordeiro de Lima; Rui Manuel Reis
Journal:  J Clin Pathol       Date:  2021-02-15       Impact factor: 3.411

4.  Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis.

Authors:  Danka J F Stuijver; Erica Romualdi; Bregje van Zaane; Leon Bax; Harry R Büller; Victor E A Gerdes; Alessandro Squizzato
Journal:  Intern Emerg Med       Date:  2014-12-13       Impact factor: 3.397

5.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.

Authors:  A A Khorana; C W Francis; E Culakova; N M Kuderer; G H Lyman
Journal:  J Thromb Haemost       Date:  2007-03       Impact factor: 5.824

6.  Tumor Mutation Burden and Cancer Treatment.

Authors:  Michael J Fusco; Howard Jack West; Christine M Walko
Journal:  JAMA Oncol       Date:  2021-02-01       Impact factor: 31.777

7.  FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors.

Authors:  Leigh Marcus; Lola A Fashoyin-Aje; Martha Donoghue; Mengdie Yuan; Lisa Rodriguez; Pamela S Gallagher; Reena Philip; Soma Ghosh; Marc R Theoret; Julia A Beaver; Richard Pazdur; Steven J Lemery
Journal:  Clin Cancer Res       Date:  2021-06-03       Impact factor: 13.801

Review 8.  The Role of Inflammation in Venous Thromboembolism.

Authors:  Brian R Branchford; Shannon L Carpenter
Journal:  Front Pediatr       Date:  2018-05-23       Impact factor: 3.418
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.